Liposarcoma medical therapy

Jump to navigation Jump to search

Liposarcoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Liposarcoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Liposarcoma medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Liposarcoma medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Liposarcoma medical therapy

CDC on Liposarcoma medical therapy

Liposarcoma medical therapy in the news

Blogs on Liposarcoma medical therapy

Directions to Hospitals Treating Liposarcoma

Risk calculators and risk factors for Liposarcoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

Medical therapy for liposarcoma includes Chemotherapy, chemoradiation, immunotherapy, and targeted therapy.

Medical Therapy

Chemotherapy

Chemoradiation

  • Sometimes the targeted therapy is given along with radiation.
  • They may be given together or at different intervals.

Targeted Therapy

Immunotherapy

Drug Type of drug
Bevacizumab Targeted therapy
Celecoxib Targeted therapy
Crizotinib Targeted therapy
Dacarbazine Chemotherapy
Dasatinib Targeted therapy
Docetaxel Chemotherapy
Doxorubicin Chemotherapy
Epirubicin hydrochloride Chemotherapy
Everolimus Chemotherapy
Gemcitabine hydrochloride Chemotherapy
Ifosfamide Chemotherapy
Imatinib mesylate Targeted therapy
Interferon alpha 2B Immunotherapy
Mesna Chemotherapy
Methotrexate Chemotherapy
Nilotinib Chemotherapy
Paclitaxel Chemotherapy
Pazopanib Targeted therapy
Regorafenib Targeted therapy
Sorafenib tosylate Targeted therapy
Sirolimus Chemotherapy
Sulindac Chemotherapy
Sunitinib malate Targeted therapy
Tamoxifen citrate Targeted therapy
Temozolomide Chemotherapy
Toremifene citrate Targeted therapy
Vinblastine citrate Chemotherapy
Vinblastine tartrate Chemotherapy

Regimen

Drugs Dose
Doxorubicin Doxorubicin 75 mg/m2; 28 day cycle
Pegylated liposomal doxorubicin 40 - 50 mg/m2 ; 28 day cycle
AI regimen Doxorubicin 25 mg/m2, Ifosfamide 3 g/m2 21 day cycle
MAID regimen Doxorubicin 20 mg/m2, Ifosfamide 2.5 g/m2, Dacarbazine 300mg/m2 21 day cycle
AD regimen Doxorubicin 20 mg/m2, Dacarbazine 300 mg/m2; 21 day cycle
Metronomic cyclophosphamide Oral daily cyclophosphamide 50mg/day for 21 days on 28 day cycle
Docetaxel-Gemcitabine Gemcitabine 900 mg/m2 , Docetaxel 100 mg/m2 for 21 day cycle
Trabectedin Trabectedin 1.5 mg/m2 21 day cycle[2]

References

  1. "NCCN Guidelines for Patients - Soft Tissue Sarcoma".
  2. "Liposarcoma".

Template:WikiDoc Sources